Hilltop Holdings Inc SEC Filings

EQT Corporation has filed a Form S-4 to register up to $3.87 billion of senior notes issued earlier this year in a private exchange. The filing launches eight, dollar-for-dollar Exchange Offers that allow holders of the unregistered “Restricted Notes” to swap them for identical series that are now registered under the Securities Act.

• Series offered range from 7.500 % Sr. Notes due 2027 to 6.500 % Sr. Notes due 2048; coupons, maturity schedules, covenants and ranking are unchanged.
• Expiration: 5:00 p.m. New York time on a 2025 date to be set; tenders may be withdrawn any time before expiry and must be made in $2,000 minimums.
• EQT will receive no cash proceeds; Restricted Notes accepted will be cancelled, leaving total debt unchanged.
• The transaction fulfils the April 2 2025 Registration Rights Agreement and prevents up to 1 pp of additional interest that would accrue if registration is delayed past 28 Mar 2026.
• Registered Notes remain senior unsecured obligations, effectively subordinated to secured debt and structurally subordinated to subsidiary liabilities.

No public market exists for either the Restricted or new Registered Notes, and EQT does not plan a listing; holders who do not exchange will retain securities subject to transfer restrictions and a likely thinner market.

Jaguar Health (JAGX) has filed a Form S-3 to register up to 1,409,732 common shares for resale by existing investors. The stock derives from (i) 481,150 shares underlying 6 % convertible Replacement Notes issued 24 Jun 2025 (conversion price $5.535–$5.555, maturity 30 Jan 2026) and (ii) 928,582 shares issuable on cash or cash-less exercise of accompanying warrants (exercise price $2.70, 18-month term). At the 23 Jul 2025 close of $2.38 the warrant strikes sit 13 % above market while the note conversion price is >130 % above market. If fully converted/exercised the new shares would expand the current 1.914 million share float by roughly 74 %, creating a sizeable overhang.

The company will not receive proceeds from secondary sales; only a full cash exercise of all warrants could raise ~$2.5 million, earmarked for working capital. The filing follows several recent financings (March convertible notes and May registered direct offering) and occurs alongside an active GI-focused drug pipeline led by crofelemer (FDA-approved Mytesi, multiple Phase 2/3 programs, orphan designations) and the October 2024 U.S. launch of Gelclair for oral mucositis. While pipeline breadth offers optionality, near-term investors must weigh dilution risk and potential price pressure from selling stockholders against the modest capital infusion possible from warrant exercises.

Global Mofy AI Limited (GMM) reports the full resolution of its April-2025 PIPE warrants. Purchasers first surrendered 25 % (≈2.55 m) of the 10.20 m warrants, leaving 7.65 m outstanding. Between 8-21 July 2025, those remaining warrants were fully exercised via the 0.8× cashless alternative, converting into 6,117,316 Class A ordinary shares. Because the exercise was cashless, the company received no incremental cash.

Following the issuance, share count stands at 25,495,761 Class A and 3,723,975 Class B shares. The new shares—about 24 % of the current Class A total—are registered under the effective Form F-1 (333-287230). This Form 6-K is also incorporated by reference into the company’s Form F-3 shelf (333-284554).

The update removes a sizeable derivative overhang, simplifying the capital structure, but simultaneously dilutes existing holders without providing fresh capital. No financial results, cash-flow data, or guidance were disclosed.

Broadcom Inc. (NASDAQ: AVGO) filed a Form 8-K dated 11 July 2025 detailing two related capital-structure actions.

1. Termination of Existing Credit Agreement (Item 1.02)
• The company repaid in full and terminated its August 15 2023 credit agreement, which originally provided a $30.4 billion term-loan facility.
• Immediately before repayment, $6.0 billion of principal was outstanding; the facility would have matured in 2028 and bore interest at a floating rate (alternate base rate or Term SOFR plus a ratings-based margin).

2. New Senior-Notes Offering (Item 8.01)
• On 7 July 2025 Broadcom executed an underwriting agreement to issue $6.0 billion of unsecured senior notes:

• $1.75 billion 4.600% notes due 2030
• $1.75 billion 4.900% notes due 2032
• $2.50 billion 5.200% notes due 2035

Strategic Implications
• The transaction shifts $6 billion of floating-rate bank debt maturing in 2028 to fixed-rate public notes maturing between 2030–2035, extending Broadcom’s maturity ladder and removing variable-rate exposure.
• No financial statements were included; therefore, changes to leverage, coverage, or liquidity ratios are not quantified within this filing.

The Bank of Nova Scotia (BNS) is offering $1,057,000 of Buffered Enhanced Participation Basket-Linked Notes maturing July 7, 2027. The unsecured senior notes provide no periodic interest and their value at maturity is entirely linked to the performance of a weighted equity basket: EURO STOXX 50 (38%), TOPIX (26%), FTSE 100 (17%), Swiss Market Index (11%) and S&P/ASX 200 (8%). The initial basket level is 100; the final level is measured on the valuation date of July 5, 2027.

Return profile:

• If the final basket level > initial level, holders receive principal plus 149% participation of the basket’s gain.
• If the basket declines ≤10% (final level ≥90), investors receive full principal (10% buffer).
• If the basket declines >10%, repayment is reduced by approximately 1.1111% for every 1% decline beyond the buffer, exposing investors to up to 100% loss of principal.

The initial estimated value is $968.53 per $1,000 note, below the 100% issue price, reflecting selling commissions (1.50%) and hedging/structuring costs. Proceeds to BNS are 98.5% of face. The notes will not be listed on any exchange; Scotia Capital (USA) Inc. and Goldman Sachs & Co. LLC may make a market but are not obligated.

Key terms:

• Participation rate: 149%
• Buffer level: 90% of initial basket
• Buffer rate: ~111.11%
• Trade date / issue date: Jul 3 2025 / Jul 11 2025 (T+5 settlement)
• Maturity: Jul 7 2027 (≈24 months)
• Denominations: $1,000 and multiples thereof
• Calculation agent: Scotia Capital Inc. (affiliate of issuer)

Risks disclosed: credit risk of BNS; market risk of basket components; lack of liquidity; potential total loss beyond the 10% buffer; issuer’s internal funding rate makes economic terms less favorable than conventional debt; conflicts of interest in hedging and market-making; no dividend participation; currency movements not hedged; initial price exceeds estimated value.

The notes suit investors seeking leveraged upside to a diversified international equity basket, willing to forgo income and accept credit and market risks as well as limited secondary liquidity.

The Schedule 13G filed on 3 July 2025 reveals that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively own 153,219 Bone Biologics Corporation (BBLG) common shares, equal to 9.99 % of the class. The position consists of 148,500 issued shares and 4,791 shares underlying Intracoastal Warrant 2; all voting and dispositive power is shared among the three reporting persons.

The stake originates from a Securities Purchase Agreement signed on 27 June 2025, under which the Company issued 60,000 shares and seven separate warrants to Intracoastal. Each warrant carries an ownership “blocker” that prevents exercise if the group’s beneficial ownership would exceed 9.99 % (or 4.99 % for several smaller warrants). Because of these blockers the group remains below the 10 % threshold required for Section 16 reporting.

Without the blocker provisions, the reporting group could control up to 821,294 shares immediately after the SPA and 719,794 shares as of 3 July 2025—more than 1.3× the 545,260 shares outstanding on 20 June 2025—indicating significant potential dilution for existing holders if the warrants become exercisable.

The certification section states the securities were not acquired to influence control of the issuer. Nonetheless, investors should monitor (1) the pace of warrant exercises, (2) any amendments to blocker thresholds, and (3) future Schedule 13D/G updates that could signal a change in intent or ownership.

The Schedule 13G filed on 3 July 2025 reveals that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively own 153,219 Bone Biologics Corporation (BBLG) common shares, equal to 9.99 % of the class. The position consists of 148,500 issued shares and 4,791 shares underlying Intracoastal Warrant 2; all voting and dispositive power is shared among the three reporting persons.

The stake originates from a Securities Purchase Agreement signed on 27 June 2025, under which the Company issued 60,000 shares and seven separate warrants to Intracoastal. Each warrant carries an ownership “blocker” that prevents exercise if the group’s beneficial ownership would exceed 9.99 % (or 4.99 % for several smaller warrants). Because of these blockers the group remains below the 10 % threshold required for Section 16 reporting.

Without the blocker provisions, the reporting group could control up to 821,294 shares immediately after the SPA and 719,794 shares as of 3 July 2025—more than 1.3× the 545,260 shares outstanding on 20 June 2025—indicating significant potential dilution for existing holders if the warrants become exercisable.

The certification section states the securities were not acquired to influence control of the issuer. Nonetheless, investors should monitor (1) the pace of warrant exercises, (2) any amendments to blocker thresholds, and (3) future Schedule 13D/G updates that could signal a change in intent or ownership.